[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"iud\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:iud":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,44,74,98,131],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100615626","phase-4-3-ml-inhaled-methoxyflurane-for-intrauterine-device-iud-insertion-100615626",false,"NCT07295054","3 mL Inhaled Methoxyflurane for Intrauterine Device (IUD) Insertion","A Double-blind Placebo-controlled Randomized Controlled Trial (RCT) of 3 mL Inhaled Methoxyflurane for Intrauterine Device (IUD) Insertion","Inclusion Criteria:\n\n1. Patients with a uterus.\n2. Ages 18 to 55 years.\n3. Undergoing any intrauterine device (IUD) insertion.\n4. English-speaking participants.\n5. Ability to use an inhaler device.\n6. Willing to receive a cervical block for their IUD insertion\n\nExclusion Criteria:\n\n1. Inability to provide informed consent.\n2. Confirmed pregnancy.\n3. Use of pain medication other than NSAIDs or acetaminophen (e.g., opioids, benzodiazepines, muscle relaxants) within 24 hours prior to the intervention.\n4. Use of cannabis within 24 hours prior to the intervention.\n5. Administration of misoprostol within 24 hours prior to the intervention.\n6. Altered level of consciousness due to any cause, including head injury, drugs, or alcohol.\n7. History of severe adverse reactions to Penthrox (methoxyflurane) or other halogenated anesthetic agents, or to any ingredient in the formulation (including non-medicinal ingredients or container components).\n8. Anatomical variance, such as distorted uterine cavity, bicornuate uterus, uterus didelphys, or cervical stenosis.\n9. Clinically significant renal and\u002For liver impairment.\n10. Known or genetic susceptibility to malignant hyperthermia.\n11. Clinically evident hemodynamic or cardiovascular instability, or respiratory depression.\n12. Not NPO according to hospital guidelines.","FEMALE","18 Years","55 Years",{"count":20,"type":21},110,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","Intrauterine device (IUD) insertion is a common contraceptive procedure often associated with moderate to severe pain, particularly among nulliparous individuals. Current pain management strategies, such as over-the-counter analgesics, are frequently inadequate. Methoxyflurane, a short-acting, self-administered inhaled analgesic, has been shown to provide rapid and effective pain relief in acute and procedural settings. This study aims to evaluate whether 3 mL of inhaled Methoxyflurane (via Penthrox inhaler) improves patient satisfaction by reducing pain and anxiety during IUD insertion.",[27],"IUD",[29,30],"Methoxyflurane","Penthrox","RECRUITING","2026-05-07",{"date":34,"type":35},"2026-05-11","ACTUAL",{"date":37,"type":35},"2026-04-27",{"date":39,"type":21},"2027-02",{"name":41,"class":42},"Women's College Hospital","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":56,"conditions":57,"keywords":60,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":72,"locationsCount":43},"100615277","assessing-pain-and-effectiveness-of-carevix-device-for-iud-insertions-100615277","NCT07290517","Assessing Pain and Effectiveness of Carevix Device for IUD Insertions","The Carevix Device: Assessing Pain and Effectiveness of a Suction-based Cervical Stabilizer for IUD Insertions in the Clinic Setting: a Randomized, Controlled Trial (CARE)","CARE","Inclusion Criteria (to be assessed prior to procedure):\n\n* Age 18 years or older\n* Able to consent on their own\n* Scheduled and will undergo an IUD insertion within 90 days of consent\n* Planned use of cervical stabilization device for placement\n* Procedure being performed by a trained provider\n* Provider is willing to use Carevix™ for scheduled procedure\n\nExclusion Criteria (to be assessed by provider at time of procedure):\n\n* Vaginal bleeding of unknown origin\n* Cervix less than 26 mm in diameter\n* Nabothian cyst on anterior lip of cervix\n* Cervical myomas\n* Cervical abnormalities\u002Fshape\n* Pregnant\n* Participants who are not fluent in and\u002For do not fully understand, read, write, or speak the English language\n* Other inability to provide informed consent to participate\n* Initial attempt to place the IUD without any cervical stabilization",{"count":53,"type":21},100,[55],"NA","The goal of this clinical trial is to evaluate patient-reported pain, bleeding, and device efficiency along with provider satisfaction and ease of use between IUD insertions using a suction cervical stabilizer (new device, FDA approved, atraumatic) and single-tooth tenaculum (standard, traumatic). Our aims are to:\n\n* assess and compare patient-reported pain during IUD insertion between the Carevix device and tenaculum.\n* assess predictors of pain scores including between nulliparous and multiparous patients\n* assess provider-reported ease of use and satisfaction\n\nParticipants (including providers) will:\n\n* be randomized to receive one device to complete the IUD procedure\n* complete a survey following the procedure",[27,58,59],"Abnormal Uterine Bleeding","Pain, Cervical",[61,62,63,64],"IUD insertion","Cervical Stabilization","Tenaculum","Pain","NOT_YET_RECRUITING","2026-01-12",{"date":68,"type":35},"2026-01-14",{"date":70,"type":21},"2026-02",{"date":39,"type":21},{"name":73,"class":42},"Indiana University",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":84,"briefSummary":85,"conditions":86,"keywords":87,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":94,"leadSponsor":96,"locationsCount":43},"100584626","use-of-cervical-cap-and-menstrual-disc-for-application-of-topical-anesthetic-prior-to-iud-insertion-100584626","NCT06891794","Use of Cervical Cap and Menstrual Disc for Application of Topical Anesthetic Prior to IUD Insertion","Use of Cervical Cap and Menstrual Disc for Application of Topical Anesthetic Prior to Intrauterine Device (IUD) Insertion","Inclusion Criteria:\n\n* Scheduled for IUD placement at the Center for Women's Health in Complex Family Planning clinic\n* Able to review and sign study consents in English\n* Generally healthy\n\nExclusion Criteria:\n\n* History of any prior births, miscarriages, or abortions after 16 weeks' gestation\n* Currently pregnant, known or suspected\n* Current stringless IUD in place\n* Participants premedicated with misoprostol\n* History of chronic pelvic pain which patients take daily medication for\n* History of endometriosis, fibroids, adenomyosis, prior cervical procedures (such as Loop Electrosurgical Excision Procedure (LEEP) or cold knife cone)\n* Any contraindications to IUD placement (per current labeling including pregnancy, fibroids that distort the uterine cavity, exam consistent with pelvic inflammatory disease, allergy to any component of the levonorgestrel intrauterine system (LNG-IUS), etc.)\n* Known allergy to eutectic mixture of local anesthetics (EMLA) or lidocaine cream, silicone, menstrual disc, or cervical cap\n* Any contraindication to EMLA or lidocaine cream, menstrual disc, or cervical cap\n* Previous IUD placement or failed attempt of an IUD placement\n* Weight \\\u003C 54.4kg (120 lbs)\n* Plan for use of oral anxiolysis, moderate\u002Fdeep sedation, or narcotics for procedure\n* Patient requesting or patient use in the past 24 hours of oral anxiolysis, moderate\u002Fdeep sedation, or narcotics\n* Any planned concomitant procedures, such as dilation and curettage (D\\&C), endometrial biopsy, colposcopy, hysteroscopy, etc.\n* Illicit drug use","45 Years",{"count":83,"type":21},24,[55],"This prospective, open label, double arm, feasibility group study will recruit participants planning to undergo office intrauterine device (IUD) placement without sedation or anxiolysis at the Center for Women's Health. Participants will self-administer a topical anesthetic using a contraceptive cervical cap or menstrual disc.\n\nTwenty-four nulliparous women will be recruited to receive one of two administration methods immediately prior to IUD placement (12 subjects in each arm): 1) menstrual disc filled with 5g eutectic mixture of local anesthetics (EMLA) cream or 2) cervical cap filled with 5g EMLA cream.",[27],[88,89],"Topical Anesthetic","IUD Insertion","2025-08-04",{"date":92,"type":35},"2025-08-08",{"date":90,"type":35},{"date":95,"type":21},"2026-04",{"name":97,"class":42},"Oregon Health and Science University",{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":105,"sex":16,"minAge":106,"maxAge":107,"enrollmentInfo":108,"targetDuration":4,"studyType":22,"phases":110,"briefSummary":111,"conditions":112,"keywords":116,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":43},"100534548","tens-unit-for-analgesia-during-iud-insertion-100534548","NCT06240260","TENS Unit for Analgesia During IUD Insertion","Utilization of Transcutaneous Electrical Nerve Stimulation (TENS) Unit for Analgesia During IUD Insertion: A Prospective Cohort Study","Inclusion Criteria:\n\n1. Persons with a uterus desiring insertion of intrauterine device\n2. Able to provide informed consent\u002Fassent\n3. Age 12-50 years old\n4. Minors 12 years of age and older will be included in the study if postmenarchal\n\nExclusion Criteria:\n\n1. Unable to provide informed consent\u002Fassent\n2. Prior cervical procedure (ie loop electrosurgical excision procedure, LEEP)\n3. Concurrent cervical or intrauterine procedure (ie colposcopy or dilation and curettage)\n4. Cutaneous damage at the TENS electrode sites\n5. Chronic or pre-procedure use of opioids\n6. Chronic pain diagnosis\n7. Prior IUD insertion\n8. Any contraindication to intrauterine device (IUD):\n\n   1. Pregnancy\n   2. Uterine anomaly that distorts the uterine cavity\n   3. Acute pelvic inflammatory disease (PID)\n   4. Postpartum endometritis or infected abortion in the past 3 months\n   5. Unexplained abnormal uterine bleeding\n   6. Wilson's disease or copper allergy (contraindication to copper IUD only)\n   7. Breast cancer (contraindication to levonorgestrel IUD only",true,"12 Years","50 Years",{"count":109,"type":21},40,[55],"Subjects will be screened over the phone or in Tufts GYN clinic for participation in the study. If eligible and interested in participating, written informed consent (and assent if applicable) will be obtained. After informed consent\u002Fassent, the patient will be enrolled in the study. The patient will decide if they desire to use TENS unit during IUD insertion appointment and inform the study team. The clinic visit will proceed as normal, with additional study proceedings as follows. The study personnel will complete the 'Background Questionnaire' with the patient prior to IUD insertion. During the IUD insertion appointment, study personnel will assist in collection of the 'Study visit' data collection form. This includes recording the patient's pain score at various time points throughout the insertion procedure:\n\n* anticipated pain during IUD insertion\n* baseline pain prior to insertion\n* speculum insertion\n* tenaculum placement\n* paracervical block administration (if performed)\n* cervical dilation (if performed)\n* uterine sounding\n* IUD insertion\n* 5 minutes after IUD insertion\n\nStudy personnel will also time the insertion procedure and collect additional data as outlined in the 'Study visit data collection form.' After IUD insertion, the participant will be asked to complete the 'Post-IUD Insertion Survey.' Once this survey is complete, this will conclude the study participation. Participation will last through the study visit only.\n\nAs part of the standard of care, a urine pregnancy test will be obtained and confirmed negative prior to IUD insertion. Patients will receive routine pain management modalities per shared decision-making with their clinical provider which may include NSAID administration, paracervical block, and heating pad.",[27,113,114,115],"Analgesia","Patient Preference","Pain, Acute",[117,118,119,120,121],"iud","contraception","iud placement","pain management","teen","2025-06-03",{"date":124,"type":35},"2025-06-04",{"date":126,"type":35},"2024-04-30",{"date":128,"type":21},"2025-12-31",{"name":130,"class":42},"Tufts Medical Center",{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":105,"sex":16,"minAge":138,"maxAge":139,"enrollmentInfo":140,"targetDuration":4,"studyType":22,"phases":142,"briefSummary":143,"conditions":144,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":43},"100506529","phase-4-intravenous-ketorolac-administration-to-attenuate-post-procedural-pain-associated-with-intrauterine-device-placement-100506529","NCT05875571","Intravenous Ketorolac Administration to Attenuate Post-procedural Pain Associated With Intrauterine Device Placement","Intravenous Ketorolac Administration to Attenuate Post-procedural Pain Associated With Intrauterine Device Placement: A Randomized, Double-Blind, Placebo-Controlled Trial","Inclusion Criteria:\n\n* Patients requiring sedated IUD placement at Arkansas Children's Hospital\n\nExclusion Criteria:\n\n* Allergy to ketorolac or other NDSAID\n* Known history of renal impairment\n* History of GI bleeding of peptic ulcer disease","13 Years","21 Years",{"count":141,"type":21},18,[24],"Intrauterine devices (IUDs) are a popular form of long-acting reversible contraception, with a high efficacy rate and few side effects. The insertion procedure for IUDs can be uncomfortable and painful. Sedation may be needed to improve patient comfort. The use of IUDs is increasing in the adolescent population, but perceived pain is a barrier to placement.\n\nPropofol is a commonly used agent for pediatric procedural sedation, but it has no analgesic properties. Ketorolac, a nonsteroidal anti-inflammatory drug, has been shown to reduce pain in adults and improve patient satisfaction when used prior to IUD placement..\n\nThe current study aims to determine if ketorolac, given in combination with propofol for IUD placement in adolescents, can improve comfort during placement and reduce pain following the procedure. Enrolled patients will receive ketorolac or placebo, in addition to propofol, for IUD placement. By comparing the outcomes of these two groups of patients, we can gain a better understanding of the optimal approach to sedation for IUD insertion in adolescents.",[27,145,146,147],"Healthy Female","Contraception","IUD Insertion Complication","2024-07-30",{"date":150,"type":35},"2024-07-31",{"date":152,"type":35},"2024-02-05",{"date":154,"type":21},"2025-06",{"name":156,"class":42},"Arkansas Children's Hospital Research Institute"]